BRAF and colorectal carcinoma: However, in BRAF-wild CRC, there was no statistically significant difference in ORR between those receiving dual-drug immunotherapy and single-drug immunotherapy (P2 ═ 0.227), despite a trend toward better efficacy (Figure 3D).